Blood
Articles in this Issue
Living the recovery: One-year qol outcomes for patients receiving ptcy gvhd prophylaxis on the access clinical trial
Abstract Background: The ACCESS trial (NCT04904588) was designed to evaluate the safety and efficacy of using peripheral blood stem cells fr...
A newly identified role for IL-5 in regulating CART-associated toxicity and efficacy
Abstract Background: CD19-directed CART cell (CART19) therapy has transformed the treatment of B-cell malignancies but is limited by life-th...
Use and outcomes following blinatumomab rechallenge in adolescents and young adults (AYA) and adults with B-cell acute lymphoblastic leukemia (B-ALL)
Abstract Introduction: Adults and AYA patients (pts) with relapsed/refractory (R/R) B-ALL have a poor prognosis, despite...
Tracking peripheral residual disease in myeloma: Clonotypic sequencing and mass spectrometry in the teclistamab era
Abstract Introduction Multiple myeloma (MM) is an incurable hematological cancer and is characterized by the proliferation of a plasma cell c...
Pre-emptive multidisciplinary approach to overcome the negative impact of high psychosocial risk factor on outcomes after allogeneic hematopoietic cell transplantation
Abstract Psychosocial factors in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) have long been recognized as...
Pathological feature in chronic myeloid leukemia patients with proteinuria receiving olverembatinib therapy
Abstract Objectives Olverembatinib is a novel 3rd-generation tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML...
Real-world post-relapse survival outcomes in children with Acute Myeloid Leukemia by race and ethnicity
Abstract Introduction: Non-Hispanic Black (NHB) and Hispanic children with acute myeloid leukemia (AML) have historically had worse overall...
A phase 2 study of luspatercept in adults and adolescents with α-thalassemia: Findings from the dose-confirmation cohort in adolescents
Abstract Introduction: α-thalassemia hemoglobin H (HbH) disease occurs when ≥2 of a patient's 4 α-globin alleles are abnormally expressed, l...
Real-world outcomes of newly diagnosed multiple myeloma patients in the veterans affairs healthcare system
Abstract Introduction: Multiple myeloma (MM) is a largely incurable hematologic malignancy with a complex and evolving therapeutic landscape....
CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study
Abstract Background Relapsed or refractory (R/R) hematologic malignancies, including T-cell acute lymphoblastic leukemia/lymphoblastic lymph...
Barriers to CAR-T cell therapy implementation in community practices: A national survey of hematologists
Abstract Background Chimeric Antigen Receptor T-cell (CAR-T) therapy offers a potentially curative option for patients w...
Treatment history, not race or duffy-null status, predicts outcomes with teclistamab in Relapsed/Refractory multiple myeloma
Abstract INTRODUCTION Bispecific antibodies represent a transformative therapy for relapsed/refractory multiple myeloma (RRMM). Teclistamab,...
Real-world characteristics and outcomes of patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who received second line therapy, stratified by stem cell transplant status
Abstract Background: DLBCL is the most common subtype of non-Hodgkin lymphoma. After first-line curative intent therapy, approximately 40% o...
Machine learning approach identifies targeting strategy for selective AML dependency
Abstract Acute myeloid leukemia (AML) remains a clinical challenge with limited targeted therapies and dismal clinical outcomes. We previous...
Enhanced VLA4-dependent endothelial cell adhesion underpins the higher efficacy of CAR-iNKT over CAR-T cells in limiting leptomeningeal acute leukemia
Abstract Invariant natural killer T (iNKT) cells are rare innate lymphocytes that bridge innate with adaptive immunity. Their invariant T ce...
Outcomes and treatment patterns of patients with primary mediastinal b-cell lymphoma after CAR-t cell therapy failure : A descar-t analysis
Abstract Background : Primary mediastinal B-cell lymphoma (PMBL) is a rare subtype of large B-cell lymphoma that usually responds well to fro...
Social determinants of health shape treatment course and long term outcomes in patients with high-risk myeloproliferative neoplasms
Abstract Introduction Myeloproliferative neoplasms (MPNs) such as Essential Thrombocythemia (ET) and Polycythemia Vera (...
IDH1/2-mutant clonal hematopoiesis: A novel driver of autoinflammatory disease
Abstract Somatic mutations in hematopoietic stem and progenitor cells (clonal hematopoiesis) are known to alter the immune milieu and can re...
Real-world CART delivery metrics: Institutional timelines from referral to infusion
Abstract Background: Timely delivery of chimeric antigen receptor T-cell (CAR-T) therapy is critical for patients with r...
The molecular landscape of Waldenström macroglobulinemia identified using whole genome sequencing
Abstract Waldenström macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by recurrent somatic mutations in MYD88 and CXCR4,...
Treatment with luspatersept exerts a pleiotropic effect on the molecular signatures of bone marrow cell subsets
Abstract Luspatercept (LUSPA) a transforming growth factor-beta (TGF-β) superfamily inhibitor is a novel agent for treating the anemia of pa...
Hyper-CVAD versus hyper-CVAD plus blinatumomab for adult patients with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis
Abstract Background While the phase II trial of Hyper-CVAD (HCVAD) with sequential blinatumomab (blina) demonstrates the benefit of blina in...
BIRC5 inhibition as a novel approach to target RAS mutant and drug-resistant multiple myeloma
Abstract Multiple myeloma (MM) is the second-most common hematological malignancy in the United States. Myeloma tumors have significant gene...
Optimizing the treatment of secondary central nervous system lymphoma (SCNSL) with intensive systemic and cns-targeted chemoimmunotherapy followed by autologous stem cell transplant (ASCT): A retrospective, single-center analysis of a modified ferreri protocol
Abstract Introduction Secondary central nervous system lymphoma (SCNSL) complicates the management of 5-15% of patients (pts) with aggressiv...
The holistic trial: A comprehensive evaluation of two second-line therapeutic approaches for immune thrombocytopenia (ITP) – a pragmatic randomized controlled trial
Abstract Background Immune thrombocytopenia (ITP) is characterized by immune mediated platelet destruction and suboptima...